Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis

被引:4
|
作者
Zloto, Ofira [1 ,2 ]
Lubetsky, Aharon [3 ]
Mizrachi, Iris Ben-Bassat [2 ]
Kesler, Anat [1 ]
Quiros, Peter A. [4 ]
Huna-Baron, Ruth [1 ,2 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[2] Sheba Med Ctr, Neuroophthalmol Unit, Tel Hashomer, Israel
[3] Sheba Med Ctr, Thrombosis & Hemostasis Unit, Tel Hashomer, Israel
[4] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA
来源
ACTA NEUROLOGICA SCANDINAVICA | 2019年 / 139卷 / 02期
关键词
cerebral venous sinus thrombosis; JAK2V617F mutation; pseudotumor cerebri; JAK2 V617F MUTATION; POLYCYTHEMIA-VERA; THROMBOEMBOLISM; RISK;
D O I
10.1111/ane.13032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation. Methods Medical records of all consecutive patients that presented with PTC and a JAK2V617F mutation who were treated were retrospectively reviewed. Data regarding demographics and ocular presenting symptoms and signs, neurological signs, hematological factors treatment, and prognosis were collected. Results The most common presenting symptoms were headache (5 patients, 83.3%) and visual obscurations (5 patients, 83.3%). CVST of the sagittal sinus and sigmoid sinus were the most common site of thrombus. Platelet count and hemoglobin count were higher than normal during follow-up. There was significant change in the disk edema degree as well as decline in retinal nerve fiber layer (RNFL) thickness (P < 0.001, P < 0.001, Matched pairs). There was no significant change in visual acuity (VA) or mean deviation (MD) during follow-up (P = 0.95, 0.64, respectively, Matched pairs). Conclusions Pseudotumor cerebri resulting from CSVT in our patients with JAK2V617F mutation was frequent in young patients and needed medical and surgical treatment, without improvement in visual functions and in third caused poor visual outcome. Therefore, we believe that a screening test for JAK2V617F mutation should be considered for patients with CVST without known risk factor presenting with PTC, especially when sagittal sinus or sigmoid sinus involvement or thrombocytosis or high hemoglobin are found upon presentation. This might lead to more aggressive management which may improve the visual prognosis of those young patients.
引用
收藏
页码:166 / 171
页数:6
相关论文
共 50 条
  • [1] JAK2V617F Mutation-positive Childhood Essential Thrombocythemia Associated With Cerebral Venous Sinus Thrombosis
    Kurosawa, Hidemitsu
    Okuya, Mayuko
    Matsushita, Takashi
    Kubota, Takeo
    Endoh, Kazushi
    Kuwashima, Shigeko
    Hagisawa, Susumu
    Sato, Yuya
    Fukushima, Keitaro
    Sugita, Kenichi
    Okada, Yoshuifumi
    Park, Myoung-Ja
    Hayashi, Yasuhide
    Arisaka, Osamu
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (09) : 678 - 680
  • [2] Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis
    Bourrienne, Marie -Charlotte
    Duchez, Veronique Le Cam
    Faille, Dorothee
    Farkh, Carine
    Nomenjanahary, Mialitiana Solo
    Gay, Juliette
    Loyau, Stephane
    Journe, Clement
    Dupont, Sebastien
    Ollivier, Veronique
    Villeval, Jean -Luc
    Plo, Isabelle
    Edmond, Valerie
    Jandrot-Perrus, Martine
    Labrouche-Colomer, Sylvie
    Cassinat, Bruno
    Verger, Emmanuelle
    Desilles, Jean -Philippe
    Ho-Tin-Noe, Benoit
    Bagan, Aude Triquenot
    Mazighi, Mikael
    Ajzenberg, Nadine
    BLOOD ADVANCES, 2024, 8 (12) : 3330 - 3343
  • [3] Characteristics of patients with cerebral sinus venous thrombosis and JAK2 V617F mutation
    Simaan, Naaem
    Molad, Jeremy
    Honig, Asaf
    Filioglo, Andrei
    Shbat, Fadi
    Auriel, Eitan
    Barnea, Rani
    Hallevi, Hen
    Seyman, Estelle
    Mendel, Rom
    Leker, Ronen R.
    Peretz, Shlomi
    ACTA NEUROLOGICA BELGICA, 2023, 123 (05) : 1855 - 1859
  • [4] The JAK2 V617F mutation in patients with cerebral venous thrombosis
    Passamonti, S. M.
    Biguzzi, E.
    Cazzola, M.
    Franchi, F.
    Gianniello, F.
    Bucciarelli, P.
    Pietra, D.
    Mannucci, P. M.
    Martinelli, I.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : 998 - 1003
  • [5] Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation
    Sun, Tiantian
    Zhang, Lei
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (04) : 374 - 381
  • [6] Thrombosis in myeloproliferative neoplasia Influence of the mutation JAK2V617F
    Guy, Alexandre
    James, Chloe
    M S-MEDECINE SCIENCES, 2019, 35 (8-9): : 651 - 658
  • [7] JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
    Xavier, S. G.
    Gadelha, T.
    Rezende, S. M.
    Zalcberg, I. R.
    Spector, N.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2011, 33 (02) : 117 - 124
  • [8] JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis
    Kumar, Narender
    Sharma, Saniya
    Binota, Jogeshwar
    Ahluwalia, Jasmina
    Varma, Neelam
    Naseem, Shano
    Chand, Ishwar
    Uppal, Varun
    Sinha, Saroj K.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (04) : 700 - 704
  • [9] JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis
    Xavier, Sandra Guerra
    Gadelha, Telma
    Pimenta, Glicinia
    Eugenio, Angela Maria
    Ribeiro, Daniel Dias
    Gomes, Fernanda Mendes
    Bonamino, Martin
    Zalcberg, Ilana Renault
    Spector, Nelson
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (06) : 1770 - 1777
  • [10] JAK2V617F mutation is associated with special alleles in essential thrombocythemia
    Hsiao, Hui-Hua
    Liu, Yi-Chang
    Tsai, Hui-Jen
    Lee, Ching-Ping
    Hsu, Jui-Feng
    Lin, Sheng-Fung
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 478 - 482